Eli Lilly Reports Zepbound Weight-Loss Comparison Data

Indianapolis, Indiana, U.S., September 30, 2026

Tirzepatide Shows Greater Weight-Loss Association

The analysis compared results from the SURMOUNT-5 clinical trial, which evaluated tirzepatide, with findings from the STEP UP clinical trial, which evaluated semaglutide 7.2 mg. Lilly reported that the indirect treatment comparison found greater average weight loss with both tirzepatide 10 mg and 15 mg compared with semaglutide 7.2 mg at the assessed time point. The analysis was designed to provide context on weight-management outcomes when direct head-to-head trial data between these specific doses are not available. For tirzepatide 10 mg, the analysis estimated an additional weight-loss advantage compared with semaglutide 7.2 mg, while the 15 mg tirzepatide dose also showed a greater estimated reduction in body weight. Lilly reported that the results remained directionally consistent across the evaluated comparison methods. The company said the findings add to the growing evidence base surrounding GIP and GLP-1 receptor agonism as an approach to chronic weight management. However, because the comparison combines data from separate studies rather than directly randomizing patients between the two treatments, the results should not be interpreted as equivalent to a head-to-head clinical trial.

Indirect Comparison Evaluates Weight Outcomes

The analysis used an established statistical approach to compare outcomes from different trials. The SURMOUNT-5 trial directly compared tirzepatide with semaglutide 2.4 mg, while the STEP UP trial evaluated higher-dose semaglutide 7.2 mg. Lilly said researchers used the available trial data to estimate how tirzepatide 10 mg and 15 mg compared with semaglutide 7.2 mg. This methodology allows investigators to generate comparative estimates when direct evidence is unavailable, but it carries important limitations because patient populations, study designs, treatment periods and other factors can differ between trials. The comparison focused on percentage change in body weight and other weight-management outcomes reported in the respective studies. The findings are particularly relevant as pharmaceutical developers continue to investigate higher-dose and next-generation incretin therapies for obesity. Both tirzepatide and semaglutide act on pathways involved in appetite regulation and metabolic control, but tirzepatide activates both the GIP and GLP-1 receptors, whereas semaglutide primarily targets the GLP-1 receptor. Differences in mechanism and dose may contribute to differences in observed weight-loss outcomes, although comparative conclusions require appropriately designed clinical trials.

Findings Add to Obesity Treatment Evidence

Obesity is a chronic disease associated with an increased risk of multiple health complications, including type 2 diabetes, cardiovascular disease and other metabolic conditions. The development of effective pharmacological treatments has expanded significantly in recent years, with GLP-1 receptor agonists and dual GIP/GLP-1 agonists becoming important components of medical weight management. The latest Lilly analysis contributes to this rapidly developing field by examining the potential differences between tirzepatide and higher-dose semaglutide using available clinical evidence. Lilly emphasized that the results represent an indirect treatment comparison and should therefore be interpreted within the limitations of the methodology. Indirect comparisons cannot fully account for every difference between separate clinical trials, even when statistical adjustments are used. Direct randomized head-to-head evidence remains important for determining comparative efficacy and safety between treatments. Nevertheless, the analysis provides additional data for researchers and healthcare professionals evaluating emerging pharmacological approaches to chronic weight management.

The findings reinforce the continued clinical development of tirzepatide and semaglutide-based therapies as pharmaceutical companies explore ways to achieve greater and more sustained weight reduction. As higher-dose formulations and new treatment strategies progress through clinical development, additional randomized trials and long-term evidence will help clarify their efficacy, safety and appropriate use in different patient populations. Lilly’s latest analysis represents another contribution to the expanding scientific literature surrounding pharmacological obesity treatment and incretin-based therapies.

Source: Eli Lilly press release